title: Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
abstract: Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
authors.affiliation: St George's Hospital & University of London, Cranmer Terrace, London, SW17 0RE, UK.
authors.forename: Vikram Sinai
authors.initials: VS
authors.lastname: Talaulikar
authors.forename: Isaac
authors.initials: I
authors.lastname: Manyonda
mesh_terms: D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000503:physiopathology; D009649:Norpregnadienes / Q000009:adverse effects / Q000627:therapeutic use*; D011980:Receptors, Progesterone; D012720:Severity of Illness Index; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D009649:Norpregnadienes; D011980:Receptors, Progesterone; C555622:ulipristal acetate
keywords: SPRM; fibroids; medical; myoma; ulipristal acetate